With coronary artery disease being one of the leading causes of death in adults, how often have you faced uncertainty regarding the heart health of your patients?
Learn how the Multifunction Cardiogram (MCG) device can bring groundbreaking and disruptive technology to your practice. A ten-minute MCG test can provide you with a comprehensive, affordable, and convenient metabolic and physiological analysis of your patient's current cardiac status. All this without having to refer them to a specialist at the risk of incurring unnecessary medical expenses.
Watch this short video for an introduction to MCG.
MCG, or Multifunction Cardiogram, is a web-based, non-invasive diagnostic tool for aiding physicians in diagnosing multiple types of heart disease, including coronary artery disease (CAD).
The MCG test’s greatest strength is its ability to identify when myocardial cellular damage has occurred, and its ability to provide data that can assist with identifying the underlying cause of such damage.
The MCG test can often uncover inflammation and damage at the cellular level, a primary driver of many cardiovascular events. The MCG test can also be used to identify decreased myocardial function, which is often an early sign of congestive heart failure.
The MCG test is often able to identify a variety of important cardiac issues at the cellular level. The MCG test is able to detect physiological damage much earlier than other modalities. Thus, the MCG device can often help identify issues before they become catastrophic.
Once it is understood that the MCG test is a physiologic analysis, one should not be surprised that the findings may not yet be confirmed by an echocardiogram, a stress test or CT angiogram because the MCG data foretells the pathology long before it is detected with these current tools.
The MCG Test conducts a physiologic analysis and evaluation of the body’s overall cardiac functions, including physical and chemical factors and processes, evaluating its weaknesses and strengths at the cellular and subcellular levels.
The MCG test is an analysis of the intrinsic frequencies of various components of the cardiac system. The MCG test is measuring the heart’s frequency signals to map the spatial separation of normal versus diseased responses from all the relevant components of the cardiac system. These components go beyond anatomical changes at the tissue level but may involve analyses at the cellular or subcellular levels.
One example of this kind analysis is the identification of ionic flow gradient patterns seen in certain channelopathies that are predictive substrates of arrhythmias. Another is the analysis of ATPase activity, which has relevance to wall motion, mitochondrial function, oxidative stress and overall ventricular function.
The clinical relevance of this information is underscored in two elegant papers: the first paper by Gerd Hasenfuss et al, described the relationship between myocardial function and the expression of sarcoplasmic reticulum Ca2+ -ATPase in the failing and nonfailing heart. The second paper, by Paul Territo et al, describes the role F0/F1-ATPase in the calcium activation of myocardial oxidative phosphorylation.
The current MCG Report consists of numbers to describe the levels of ischemia, as well as pluses (+) and minuses (-) to indicate the threshold level of clinical relevance of various specific characteristic physiologic/pathologic markers. As stated earlier one should not be surprised that the findings may not yet be confirmed by an echocardiogram, a stress test or CT angiogram because the MCG data provides early indications of the pathology long before it is detected with these current tools.
Clinical studies have shown that MCG has a sensitivity of 90+% with a 7 (+/- 2)% false negative results and a specificity of 85+% with 15 (+/- 3)% false positive results in detecting ischemia due to coronary artery disease.
Among parties with more than 70% coronary artery atherosclerotic plaque luminal encroachments in single of multiple vessels, without any collateral circulation, MCG detection rate is approximately 90% or better.
MCG has an accuracy of approximately 90% in detecting patients with 50% or greater obstruction of the left main coronary artery and/or 70% or greater blockage in the other large coronary arteries (e.g. LAD or L. Circ).
Detection rates and diagnostic accuracy are unaffected by gender, age, or race. MCG assumes that subjects have normal or corrected serum electrolyte chemistry and completed blood count. It also assumes that the subject has no structural anomalies of the myocardium.
There are roughly 15 (+/- 3)% false positive cases which include: coronary artery vasospasms, coronary arteriopathy, microvascular disease, aortic stenosis, hypertensive heart disease and metabolic disorders, untreated or under-treated anemia, renal disease, angiographer under-estimation of the degree of obstruction, and poor quality ECG tracings.
There are about 7 (+/- 2)% false negative cases which include: well-established coronary collateral circulations with visibly poor coronary angiogram results, coronary angiograms results showed moderate luminal encroachments with negative MCG test, patients with pharmacologically reversible obstructive coronary artery disease under single vasodilator therapy, and poor quality ECG tracings
The secondary findings of each test (such as MI, LVH, arrhythmias, etc) should be considered as a reference or an expert's opinion rather than definitive diagnosis. Results of the report are an aid to diagnosis, not a diagnosis itself.
Review double-blind clinical trials for the MCG machine
Review published papers, articles, and abstracts
Review presentations from Dr. Joseph Shen and Dr. Linda Papa